BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...shielded cell therapy. The products encapsulate engineered cells in a bio-compatible matrix; Sigilon’s first product, SIG-001...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...and Morningside. Tencent, Sequoia China, China Life, SIG...
BioCentury | Sep 17, 2020
Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

...significance "more robust than just a standard stat-sig...
BioCentury | Mar 17, 2020
Finance

Sigilon nears first clinical test of cell shielding tech with $80M series B

...The funds will enable Sigilon to start a first-in-human trial of its hemophilia A therapy SIG-001...
...four INDs over the next two years, Sigilon President and CEO Rogerio Vivaldi told BioCentury. SIG-001...
...to flow in; and allow the therapeutic proteins to flow out, Vivaldi said. In mice, SIG-001...
BioCentury | Aug 22, 2019
Financial News

Microbiome company Finch raises $53M ahead of anti-infective readout

...the trial's results show a level of statistical significance "more robust than just a standard stat-sig...
BioCentury | May 1, 2019
Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

...at the American Society of Gene and Cell Therapy meeting showing its engineered cell therapy SIG-001...
...time in a mouse model of hemophilia A, supporting the company's IND this year for SIG-001...
BioCentury | Nov 2, 2018
Financial News

XtalPi raises $46M in series B extension

...in a series B-1 extension round led by China Life Healthcare Fund. Also participating were SIG...
BioCentury | May 3, 2017
Distillery Techniques

Drug delivery

...7, 2017 doi:10.1016/j.xphs.2017.01.034 CONTACT: Jin Han, Inje University, Busan, South Korea email: phyhanj@inje.ac.kr CONTACT: Joon Sig...
BioCentury | Jan 20, 2017
Clinical News

DMT210: Ph II DMT210-003 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-003 trial to evaluate DMT210 5% topical gel twice daily for 12 weeks in about 104 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see...
BioCentury | Dec 9, 2016
Clinical News

DMT210: Ph II DMT210-02 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-002 trial to evaluate twice-daily topical DMT210 gel for 28 days in 25 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27,...
Items per page:
1 - 10 of 21
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...shielded cell therapy. The products encapsulate engineered cells in a bio-compatible matrix; Sigilon’s first product, SIG-001...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...and Morningside. Tencent, Sequoia China, China Life, SIG...
BioCentury | Sep 17, 2020
Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

...significance "more robust than just a standard stat-sig...
BioCentury | Mar 17, 2020
Finance

Sigilon nears first clinical test of cell shielding tech with $80M series B

...The funds will enable Sigilon to start a first-in-human trial of its hemophilia A therapy SIG-001...
...four INDs over the next two years, Sigilon President and CEO Rogerio Vivaldi told BioCentury. SIG-001...
...to flow in; and allow the therapeutic proteins to flow out, Vivaldi said. In mice, SIG-001...
BioCentury | Aug 22, 2019
Financial News

Microbiome company Finch raises $53M ahead of anti-infective readout

...the trial's results show a level of statistical significance "more robust than just a standard stat-sig...
BioCentury | May 1, 2019
Preclinical News

May 1 Preclinical Quick Takes: MD Anderson, Sana, Sigilon

...at the American Society of Gene and Cell Therapy meeting showing its engineered cell therapy SIG-001...
...time in a mouse model of hemophilia A, supporting the company's IND this year for SIG-001...
BioCentury | Nov 2, 2018
Financial News

XtalPi raises $46M in series B extension

...in a series B-1 extension round led by China Life Healthcare Fund. Also participating were SIG...
BioCentury | May 3, 2017
Distillery Techniques

Drug delivery

...7, 2017 doi:10.1016/j.xphs.2017.01.034 CONTACT: Jin Han, Inje University, Busan, South Korea email: phyhanj@inje.ac.kr CONTACT: Joon Sig...
BioCentury | Jan 20, 2017
Clinical News

DMT210: Ph II DMT210-003 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-003 trial to evaluate DMT210 5% topical gel twice daily for 12 weeks in about 104 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see...
BioCentury | Dec 9, 2016
Clinical News

DMT210: Ph II DMT210-02 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-002 trial to evaluate twice-daily topical DMT210 gel for 28 days in 25 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27,...
Items per page:
1 - 10 of 21